
The antitrust watchdog in India is examining a case against Compagnie de Saint-Gobain, which alleges that the French company compelled certain partners to exclusively purchase glass from them or face potential supply exclusion. This information was detailed in documents reviewed by Reuters.
A case was filed against Saint-Gobain and their local unit to the Competition Commission of India (CCI) in May by an unidentified retired glass industry executive who requested confidentiality, according to Reuters.
Saint-Gobain has been accused of market position abuse in the float glass and coated glass variants. They hold a 44% share of the Indian float glass market and a 19% share of the coated glass market, according to documentation.
Related: India Watchdog Fines MakeMyTrip, Oyo For Anti-competitive Practices
Saint-Gobain said in a statement to Reuters it was not aware of and nor had it been served any complaint, notice or document. The group and its India unit, Saint-Gobain India Private Limited, “conduct their activities in compliance with laws”, in particular competition law, it said.
The CCI did not respond to a request for comment. It does not, as per policy, disclose details of cases filed or under review.
The May 25 case documents allege Saint-Gobain entered into agreements with glass processors, forcing them to “exclusively” purchase glass from the company or face stopped supplies if that obligation is not fulfilled.
Featured News
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Live Nation Under Criminal Antitrust Investigation Over Pandemic-Era Refund Policies
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas